Kornimate/medical-research-clean huggingface dataset:
embraceplus spo2 accuracy validation

Conditions: Oximetry

Summary: the aim of this study is to test the accuracy of embraceplus computed spo2 during mild, moderate and severe hypoxia (a lower-than-normal concentration of oxygen in arterial blood); ie, a range of arterial hbo2 saturations from 100 to down to 70%. this is done by comparing the reading of the the subject device during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin (hemoglobin carrying oxygen) saturation, that is arterial blood sample processed in a laboratory.


Eligibility criteria:
inclusion criteria: * the subject is male or female, aged ≥18 and \<50. * the subject is in good general health with no evidence of any medical problems. * the subject is fluent in both written and spoken english. * the subject has provided informed consent and is willing to comply with the study procedures. exclusion criteria: * the subject is obese (bmi\>30). * the subject has a known history of heart disease, lung disease, kidney or liver disease. * diagnosis of asthma, sleep apnea, or use of cpap. * subject has diabetes. * subject has a clotting disorder. * the subject a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation. * the subject has any other serious systemic illness. * the subject is a current smoker. * any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators' would interfere with the sensors working correctly. * the subject has a history of fainting or vasovagal response. * the subject has a history of sensitivity to local anesthesia. * the subject has a diagnosis of raynaud's disease. * the subject has unacceptable collateral circulation based on exam by the investigator (allen's test). * the subject is pregnant, lactating or trying to get pregnant. * the subject is unable or unwilling to provide informed consent, or is unable or unwilling to comply with study procedures. * the subject has any other condition, which in the opinion of the investigators' would make them unsuitable for the study.

Keywords: oximetry wearable spo2
peri-operative dexmedetomidine infusion in pre-eclamptic patients

Conditions: Pre-Eclampsia

Summary: the purpose of this study is to investigate the effects of dexmedetomidine infusion on the stress response to intubation, postoperative analgesia, and renal functions (urinary output \[uop\], creatinine and glomerular filtration rate \[gfr\]) in preeclamptic patient.


Eligibility criteria:
inclusion criteria: * pregnant women * have mild preeclampsia ( pre-eclamptic patients will be defined as having hypertension \[systolic blood pressure (sbp) ≥140 mmhg and/or diastolic blood pressure (dbp)≥90 mmhg\] accompanied by proteinuria first detected after 20 weeks of gestation). * proteinuria is defined as at least 300 mg protein in 24 h urine collection \[or ≥1+ dipstick (30 mg/dl) in a single urine sample\] ). * american society of anesthesiologists (asa) physical status of ii or iii. * age between 19 and 40 years exclusion criteria: * patient refusal to consent (obsolete). * pre-existing neurological disease or psychic patients. * history of cardiac and respiratory system failure. * co-existing significant renal or liver disease.
safety and efficacy of osteoform (rhpth [1-34]) in increasing bone mineral density in osteoporosis

Conditions: Osteoporosis

Summary: osteoform, containing recombinant (rhpth \[1-34\]), enhances bone mineral density and reduces risk for vertebral fracture. this study evaluates the safety and efficacy of osteoform in the treatment of osteoporosis in post-menopausal women.

207 post-menopausal women were enrolled for screening at 6 centres, and supplemented with daily 1000 mg elemental calcium and 500 iu of vitamin d for 45 days. 82 eligible women with osteoporosis were randomly received daily either calcium and vitamin d alone (control group) or osteoform 20 µg subcutaneously with calcium and vitamin d (drug group) for 12 months. end points such as percentage of increase in bone mineral density and, changes in bone biomarkers (serum osteocalcin, bone specific alkaline phosphatase, and urinary dpd) were evaluated at baseline, and 6 and 12 months after supplementation. besides, safety parameters and adverse events were monitored through out the study period.

Eligibility criteria:
inclusion criteria: postmenopausal women with osteoporosis (lumbar spine or femoral neck bmd or total hip t-score less than or equal to-2.5) exclusion criteria: 1. women with vertebral (l1-l4) abnormalities that preclude accurate measurement by dexa. 2. women on medications that are known to affect bone for more than 7 days in the past 6 months. 3. currently taking systemic prednisone, inhaled steroids, anticoagulants, anticonvulsants. 4. history of rhpth use or known hypersensitivity to study drug. 5. vitamin d3 deficiency (vitamin d3 \< 20 ng/ml). 6. abnormal thyroid function. 7. history of kidney disease. 8. any history of hypercalciuria, hypercalcemia or hyperparathyroidism. 9. history of active or treated tuberculosis or significant liver disease or gastrointestinal disease or cancer.

Keywords: rhpth(1-34) osteoporosis
role of cardioflux in predicting coronary artery disease (cad) outcomes

Conditions: Coronary Artery Disease

Summary: this single-center clinical trial is designed to evaluate the cardioflux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (mace) in patients referred for evaluation for coronary artery disease.

this is a single-center, prospective, observational cohort trial to form a registry data set. patients presenting for cardiac stress testing utilizing single photon emission computed tomography (spect), cardiac ct angiography (ccta), or cardiac catheterization will be offered to enroll in the registry and provide informed consent to undergo imaging with a cardioflux magnetocardiography (mcg) prior to their procedure. multiple studies have shown that mcg accuracy is quite high in identifying patients with symptomatic coronary artery disease. this difference is dramatic enough to prove superiority over standard ecgs in diagnosis of vital ischemic and infarction parameters. genetesis presents a novel mcg analysis system called cardioflux (cf). this modality takes less than five minutes to complete, is radiation-free, and is an easy to operate system. this clinical trial will enroll patients of all cardiac risk levels presenting for various modalities of cardiac diagnostic testing to have cardioflux scanning in addition to standard of care. results will be interpreted and compared to the immediate results of nuclear (spect) stress testing, cardiac ct angiography, or cardiac catheterization. participants will be followed up at 30 days and 1 year via phone call or chart review. 30 day and 1 year mace will be recorded and correlated with initial cardioflux mcg results. sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv), and overall accuracy will be calculated of cardioflux relative to the incidence of mace, and in comparison to the above diagnostic modalities.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age at the time of enrollment. * patient presenting for cardiac stress testing, cardiac ct angiography (ccta), or cardiac catheterization. * consents to having an magnetocardiogram-cardioflux study scan. exclusion criteria: * \< 18 years of age * patients unable to fit into device * non-ambulatory patients * patients with implanted cardiac pacemakers/defibrillators * positive response on provided metallic/ferromagnetic device screening form * atrial fibrillation with rapid ventricular response * patients with other sustained or incessant arrhythmias * patients with claustrophobia or unable to lie supine for 2 minutes * patients require supplemental oxygen at home * presence or reasonable clinical suspicion of any acute coronary syndrome for which delayed intervention could increase the risk or magnitude of damaged myocardium * patients scheduled for cardiac catheterization with indication of valvular disease * poor candidate for follow-up (e.g. no access to phone) * prisoners * repeat participants * patients participate in other research studies

Keywords: coronary artery disease cardiac imaging
effect of daily music listening on stroke recovery

Conditions: Stroke

Summary: single blind randomized clinical trial including 50 stroke patients to investigate the effect of daily music listening on behavioral, neural and physiological recovery. patients are randomized (1:1:1) to listen instrumental or vocal music, or audiobooks (recorded book reading) (control). outcome measures are change in neuropsychological tests, change in self-reported mood, structural and functional magnetic resonance imaging changes and hormonal changes performed at acute, 3-month and 6-month stages.

please see above

Eligibility criteria:
inclusion criteria: * acute hemispheral stroke exclusion criteria: * previous neurological or current psychiatric disease, * severe aphasia

Keywords: stroke recovery music
peripheral intravenous central catheter intervention in preterm infants

Conditions: Preterm; Pain, Acute; Stress; Nursing Caries

Summary: this study will be conducted to evaluate the effect of grasping reflex stimulation applied during peripheral intravenous central catheter (pic) intervention on pain and stress in preterm infants receiving treatment and care in the neonatal intensive care unit.

the study was planned in a parallel randomized controlled trial design. the population of the research will be preterm infants followed in the newborn intensive care unit of atatürk university health research and application center between may 2022 and september 2022. randomization in the sample of the study will be done in the computer environment. sample size was determined by power analysis. in the collection of data; preterm baby information form, preterm baby follow-up form, neonatal stress scale and alps-neo pain and stress assessment scale will be used. in the control group, the pic intervention will be performed by the investigator in accordance with clinical procedures. in the experimental group, the baby's grasping reflex stimulation will be provided during the pic attempt.

Eligibility criteria:
inclusion criteria: * between 26-32 weeks of gestation, * birth weight of 1500 g and below, * no congenital defects * who need pic intervention while receiving treatment and care in the nicu, * not receiving sedation at least 3 hours before the pic procedure, * no neurological problems * no surgical intervention * recipient of noninvasive mechanical ventilation * infants whose parents approved the informed voluntary consent form exclusion criteria: * painful procedure (invasive procedure, etc.) has been performed in the last hour, * infants without parental informed consent form

Keywords: preterm pain, acute stress nursing caries
selinexor plus high-dose melphalan (hdm) before autologous hematopoietic cell transplantation for multiple myeloma

Conditions: Multiple Myeloma

Summary: phase i: the primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (mtd) of selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. phase ii: the primary purpose of this study phase is to assess the complete response (cr) conversion rate.


Eligibility criteria:
inclusion criteria: * 18 years of age or older with histologically confirmed multiple myeloma * achieving partial response (pr) or very good partial response (vgpr) with systemic chemotherapy * received less than 4 lines of anti-myeloma therapy. * karnofsky performance status of \>= 70% * adequate pulmonary, cardiac, hepatic and renal function as outlined in the protocol * signed informed consent form in accordance with institutional policies prior to the initiation of high-dose therapy exclusion criteria: * non-secretory multiple myeloma * have achieved complete response (cr) prior to autologous hematopoietic cell transplantation (hct) * central nervous system (cns) involvement * uncontrolled bacterial, viral or fungal infections * myocardial infarction within 6 months prior to enrollment or has new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * prior malignancies within the last 5 years except resected basal cell carcinoma or treated cervical carcinoma in situ. * females who are pregnant or breastfeeding * have received other investigational drugs within 14 days prior to screening * prior autologous or allogeneic hct * prior organ transplant or autoimmune disease requiring immunosuppressive therapy

Keywords: autologous hematopoietic cell transplantation (hct) high-dose melphalan selinexor
integrated diabetes management protocol using smartphone

Conditions: Diabetes

Summary: the investigators aim to assess whether using integrated diabetes management protocol using smartphone would increase glucose control among diabetes patients.

smartphones and digital healthcare is expected to provide better diabetes care. the investigators aim to assess whether using integrated diabetes management protocol using smartphone would increase glucose control among diabetes patients. smartphone apps for food diary, activity monitor, blood glucose will be used for three months. blood glucose control and patient satisfaction will be assessed.

Eligibility criteria:
inclusion criteria: * type 2 diabetes, type 1 diabetes, gestational diabetes exclusion criteria: * medications which interfere glucose control * cancer * chronic kidney injury
validation of kaihani score for gambling addiction

Conditions: Gambling Addiction

Summary: the kaihani score is a blood based means of assessing molecules believed to be associated with gambling addiction. the current clinical trial will assess the kaihani score in 3 groups: group 1: 10 patients with no personal or family problems with gambling as assessed by the pg-ybocs (obsessions-compulsions scale yale-brown (y-bocs), adapted for pathological gambling) (pg-ybocs). group 2: 10 patients with moderate gambling addiction as assessed by the pg-ybocs (obsessions-compulsions scale yale-brown (y-bocs), adapted for pathological gambling) (pg-ybocs). group 3: 10 patients with severe gambling addiction as assessed by the pg-ybocs (obsessions-compulsions scale yale-brown (y-bocs), adapted for pathological gambling) (pg-ybocs). the goal of the study is to confirm preliminary efficacy of the kaihani score as a blood based means of assessing gambling propensity.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of pathological gambling (dsm iv criteria) * first-time consultants. * without psychotropic treatment or treatment with a stable and unchanged for over a month. exclusion criteria: * pregnant women and patients with hearing disorders * epilepsy (untreated or poorly balanced) * focal brain injury, whatever its origin (vascular, traumatic, tumor or infectious) * history of head trauma with loss of consciousness, * administration of drugs or substances lowering the seizure threshold * sleep deprivation, jet lag, or drug withdrawal. * participants with a problem of uncorrected visual acuity. * other current addiction.

Keywords: addiction bdnf
postoperative pain after dental post application

Conditions: Postoperative Pain; Endodontically Treated Teeth; Vibration; Exposure

Summary: in this study the effect of dental post application on postoperative dental pain in patients with asymptomatic teeth after a single-appointment root canal treatment will be evaluated.

the aim of this clinical study is to evaluate the effect of dental post application on postoperative pain intensity level in patients with asymptomatic teeth after a single-appointment root canal treatment. a total of one hundred patients with asymptomatic teeth and with no contradictory medical history who are indicated for non-surgical root canal treatment and application of a dental post at the endodontic clinic, faculty of dentistry, istanbul medipol university, between april and december of 2019 will be included. all of the patients will be recruited from the istanbul medipol university dental clinics in istanbul. the patients will be divided in two groups (n=50). consent will be obtained from all study participants before the treatment. after the root canal treatments are completed in single-visit, in the first groups dental posts will be applied immediately at the same visit and patients will be appointed for pain assessment. in group 2 after the root canal treatment a temporary filling be applied in the access cavity and patients will be appointed for pain assessment. dental posts will be applied after the pain assessment is completed at the end of 1 week. all treatments will be performed by one endodontist. postoperative pain intensity will be assessed at 24, 48, and 72 h; 7 days; after the treatment. the teeth will be examined according to postoperative pain intensity levels,

Eligibility criteria:
inclusion criteria: * patients with asymptomatic teeth which were in need of orthograde non-surgical root canal treatment with post application exclusion criteria: patients * who were younger than 18 years old, * who had contradictory medical history for root canal treatment, * who used antibiotics 1 month prior and analgesics 1 week prior to the treatment, * who could not abide the follow-up time teeth * that were symptomatic * with previous root canal treatment * with present or suspected vertical root fracture * with ≥ 4 mm periodontal pocket depth * with apical lesions ≥ 5mm * with damaged or resorbed apex * that were in need of apical surgery

Keywords: dental posts postoperative pain single-visit root canal treatment two-visit root canal treatment vibration
trial of velcade and rituxan as front-line tx for low-grade nhl

Conditions: Non-Hodgkin's Lymphoma

Summary: bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. monoclonal antibodies, such as rituximab, can block cancer growth in different ways. some block the ability of cancer cells to grow and spread. others find cancer cells and help kill them or carry cancer-killing substances to them. giving bortezomib together with rituximab may kill more cancer cells. this phase ii trial is studying how well giving bortezomib together with rituximab works as first-line therapy in treating patients with low-grade b-cell non-hodgkin's lymphoma.

this is a multicenter, prospective study. * induction therapy: patients receive bortezomib iv over 3-5 seconds on days 1, 8, 15, and 22. patients also receive rituximab iv on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. treatment repeats every 35 days for 3 courses. patients achieving a complete response, partial response, or stable disease proceed to maintenance therapy. * maintenance therapy: beginning 6-8 weeks after induction therapy, patients receive bortezomib iv over 3-5 seconds and rituximab iv on day 1. treatment repeats every 60 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. blood and tissue samples are collected at baseline and periodically during study treatment. after completion of study therapy, patients are followed every 3 months for 2 years.

Eligibility criteria:
inclusion criteria: * histologically confirmed low-grade b-lymphocyte non-hodgkins lymphoma * life expectancy \> 12 months exclusion criteria: * no known history of hiv infection * no other active infection * no peripheral neuropathy ≥ grade 2 within the past 14 days * no uncontrolled hypertension * none of the following cardiac conditions: * myocardial infarction within the past 6 months * no heart failure * uncontrolled angina * severe uncontrolled ventricular arrhythmias * electrocardiographic evidence of acute ischemia * active conduction system abnormalities * no serious medical or psychiatric illness that would preclude study compliance * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no prior therapy for non-hodgkins lymphoma * no prior bortezomib or rituximab * at least 3 weeks since prior chemotherapy, radiation therapy, immunotherapy, systemic anticancer biologic therapy, or anticancer hormonal therapy * at least 2 weeks since prior investigational drugs * no other concurrent systemic cytotoxic chemotherapy or investigational agents + no leukemia

Keywords: non-hodgkin's lymphoma
single and multiple ascending dose study assessing the safety, tolerability, pk and pd of ag10

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related

Summary: this is a single center, prospective, randomized, placebo-controlled study of ag10 in healthy adult subjects

up to 48 healthy volunteers will be given a single dose of ag10 or placebo and be monitored for safety and tolerability over a 5-day period. up to 48 healthy volunteers will be given multiple doses of ag10 or placebo and be monitored for safety and tolerability over a 15-day period.

Eligibility criteria:
inclusion criteria: * weight between \>50 kg and ≤110 kg; * bmi of 18 to 32 kg/m2; * subjects who are healthy as determined by medical history, physical examination, 12 lead ecg and standard laboratory tests; * subjects who are negative for drugs of abuse and alcohol tests; * subjects who are non-smokers; exclusion criteria: * subjects who have used prescription drugs within 4 weeks of first dosing; * subjects who have a prior cholecystectomy; * subjects who have used any over-the-counter medications within 7 days prior to day -1; * subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders; * subjects who have an abnormal screening ecg;